{"id":797880,"date":"2025-01-06T07:33:50","date_gmt":"2025-01-06T12:33:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-launches-the-ctech-solovpe-plus-system\/"},"modified":"2025-01-06T07:33:50","modified_gmt":"2025-01-06T12:33:50","slug":"repligen-launches-the-ctech-solovpe-plus-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/repligen-launches-the-ctech-solovpe-plus-system\/","title":{"rendered":"Repligen Launches the CTech\u2122 SoloVPE\u00ae PLUS System"},"content":{"rendered":"

\nNext-Generation At-Line Concentration Measurement for Bioprocessing
\n<\/h2>\n
\n

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech\u2122 SoloVPE\u00ae<\/sup> PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in complex biological production workflows, from process development scale through cGMP manufacturing.<\/p>\n

As the bioprocess industry shifts toward higher drug concentration formulations to improve efficiency and reduce production costs, there has been a growing need for faster, more reliable and more accurate analytical tools. The SoloVPE PLUS System addresses this need, utilizing variable pathlength spectroscopy to deliver precise concentration measurements in under 30 seconds, without the need for dilution or background correction.<\/p>\n

This innovative technology is a significant addition to Repligen\u2019s process analytics portfolio, advancing the company\u2019s at-line capabilities and complementing both its in-line, real-time FlowVPX\u00ae<\/sup> System and fully integrated RPM\u2122 (Real-time Process Management) TFF Systems. Applications for the SoloVPE PLUS System include measurement of protein concentration (such as for antibody-based drugs, including ADC drug-to-antibody ratio), quantitation of nucleic acids (DNA\/RNA) and measurement of mRNA in mRNA-based therapeutics.<\/p>\n

Olivier Loeillot, President and Chief Executive Officer at Repligen said, \u201cThe next-generation SoloVPE PLUS System is a success for our development team, delivering on the goal to achieve a new level of speed, precision and reproducibility. It\u2019s an exciting advance for Repligen – and just the first of many new product launches we have planned for 2025.\u201d<\/p>\n

Kola Otitoju, Senior Vice President and Global Head of Process Analytics, said, \u201cRepligen is at the forefront of PAT innovation, and the new SoloVPE PLUS System showcases our ability to evolve our bioprocessing technologies to meet our customers\u2019 needs. The SoloVPE PLUS System delivers on the key performance factors required to support faster decision-making and greater efficiency, helping our customers improve both their productivity and bottom line.”<\/p>\n

The SoloVPE PLUS System offers several key advantages over current UV-Vis spectroscopy offerings in the market:<\/p>\n